Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure

Charlotte Andersson; Gunnar H Gislason; Casper H Jørgensen; Peter R Hansen; Allan Vaag; Rikke Sørensen; Charlotte Mérie; Jonas B Olesen; Peter Weeke; Michelle Schmiegelow; Mette L Norgaard; Lars Køber; Christian Torp-Pedersen

doi:10.1016/j.diabres.2011.07.011

Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure

Charlotte Andersson, Gunnar H Gislason, Casper H Jørgensen, Peter R Hansen, Allan Vaag, Rikke Sørensen, Charlotte Mérie, Jonas B Olesen, Peter Weeke, Michelle Schmiegelow, Mette L Norgaard, Lars Køber, Christian Torp-Pedersen

21 Citations (Scopus)

Abstract

Aims: The aim was to investigate the outcomes of individual sulfonylureas in patients with heart failure (HF). Methods: All patients hospitalized with HF for the first time in 1997-2006, alive 30 days after discharge, and who received anti-diabetic monotherapy with glimepiride (n= 1097), glibenclamide (glyburide) (n= 1031), glipizide (n= 557), gliclazide (n= 251), or tolbutamide (n= 541) were identified from nationwide registers. Risk of all-cause mortality was assessed by multivariable Cox regression models. Results: Over the median observational time of 744 (Inter Quartile Range 268-1451) days, 2242 patients (64%) died. The analysis demonstrated similar hazard ratio (HR) for mortality for treatment with glimepiride (1.10 [95% confidence interval 0.92-1.33]), glibenclamide (1.12 [0.93-1.34]), glipizide (1.14 [0.93-1.38]), tolbutamide (1.04 [0.85-1.26]), and gliclazide (reference). Grouped according to pancreatic specificity, i.e., with tolbutamide, glipizide, and gliclazide as specific, and glibenclamide, and glimepiride as non-specific agents, no differential prognosis was found between the two groups (HR 1.04 [0.96-1.14], for non-specific, compared to pancreas specific agents). The prognosis was not dependent on prior acute myocardial infarction or ischemic heart disease (p for interactions >0.3). Conclusions: In current clinical practice, it is unlikely that there are considerable differences in risk of mortality associated with individual sulfonylureas in patients with heart failure.

Original language	English
Journal	Diabetes Research and Clinical Practice
Volume	94
Issue number	1
Pages (from-to)	119-25
Number of pages	7
ISSN	0168-8227
DOIs	https://doi.org/10.1016/j.diabres.2011.07.011
Publication status	Published - Oct 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.diabres.2011.07.011

Cite this

Andersson, C., Gislason, G. H., Jørgensen, C. H., Hansen, P. R., Vaag, A., Sørensen, R., Mérie, C., Olesen, J. B., Weeke, P., Schmiegelow, M., Norgaard, M. L., Køber, L., & Torp-Pedersen, C. (2011). Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Research and Clinical Practice, 94(1), 119-25. https://doi.org/10.1016/j.diabres.2011.07.011

Andersson, C, Gislason, GH, Jørgensen, CH, Hansen, PR , Vaag, A, Sørensen, R, Mérie, C, Olesen, JB, Weeke, P, Schmiegelow, M, Norgaard, ML, Køber, L & Torp-Pedersen, C 2011, 'Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure', Diabetes Research and Clinical Practice, vol. 94, no. 1, pp. 119-25. https://doi.org/10.1016/j.diabres.2011.07.011

@article{db8830b996394c20a1d38f68277865a0,

title = "Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure",

abstract = "Aims: The aim was to investigate the outcomes of individual sulfonylureas in patients with heart failure (HF). Methods: All patients hospitalized with HF for the first time in 1997-2006, alive 30 days after discharge, and who received anti-diabetic monotherapy with glimepiride (n= 1097), glibenclamide (glyburide) (n= 1031), glipizide (n= 557), gliclazide (n= 251), or tolbutamide (n= 541) were identified from nationwide registers. Risk of all-cause mortality was assessed by multivariable Cox regression models. Results: Over the median observational time of 744 (Inter Quartile Range 268-1451) days, 2242 patients (64%) died. The analysis demonstrated similar hazard ratio (HR) for mortality for treatment with glimepiride (1.10 [95% confidence interval 0.92-1.33]), glibenclamide (1.12 [0.93-1.34]), glipizide (1.14 [0.93-1.38]), tolbutamide (1.04 [0.85-1.26]), and gliclazide (reference). Grouped according to pancreatic specificity, i.e., with tolbutamide, glipizide, and gliclazide as specific, and glibenclamide, and glimepiride as non-specific agents, no differential prognosis was found between the two groups (HR 1.04 [0.96-1.14], for non-specific, compared to pancreas specific agents). The prognosis was not dependent on prior acute myocardial infarction or ischemic heart disease (p for interactions >0.3). Conclusions: In current clinical practice, it is unlikely that there are considerable differences in risk of mortality associated with individual sulfonylureas in patients with heart failure.",

author = "Charlotte Andersson and Gislason, {Gunnar H} and J{\o}rgensen, {Casper H} and Hansen, {Peter R} and Allan Vaag and Rikke S{\o}rensen and Charlotte M{\'e}rie and Olesen, {Jonas B} and Peter Weeke and Michelle Schmiegelow and Norgaard, {Mette L} and Lars K{\o}ber and Christian Torp-Pedersen",

year = "2011",

month = oct,

doi = "10.1016/j.diabres.2011.07.011",

language = "English",

volume = "94",

pages = "119--25",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure

AU - Andersson, Charlotte

AU - Gislason, Gunnar H

AU - Jørgensen, Casper H

AU - Hansen, Peter R

AU - Vaag, Allan

AU - Sørensen, Rikke

AU - Mérie, Charlotte

AU - Olesen, Jonas B

AU - Weeke, Peter

AU - Schmiegelow, Michelle

AU - Norgaard, Mette L

AU - Køber, Lars

AU - Torp-Pedersen, Christian

PY - 2011/10

Y1 - 2011/10

N2 - Aims: The aim was to investigate the outcomes of individual sulfonylureas in patients with heart failure (HF). Methods: All patients hospitalized with HF for the first time in 1997-2006, alive 30 days after discharge, and who received anti-diabetic monotherapy with glimepiride (n= 1097), glibenclamide (glyburide) (n= 1031), glipizide (n= 557), gliclazide (n= 251), or tolbutamide (n= 541) were identified from nationwide registers. Risk of all-cause mortality was assessed by multivariable Cox regression models. Results: Over the median observational time of 744 (Inter Quartile Range 268-1451) days, 2242 patients (64%) died. The analysis demonstrated similar hazard ratio (HR) for mortality for treatment with glimepiride (1.10 [95% confidence interval 0.92-1.33]), glibenclamide (1.12 [0.93-1.34]), glipizide (1.14 [0.93-1.38]), tolbutamide (1.04 [0.85-1.26]), and gliclazide (reference). Grouped according to pancreatic specificity, i.e., with tolbutamide, glipizide, and gliclazide as specific, and glibenclamide, and glimepiride as non-specific agents, no differential prognosis was found between the two groups (HR 1.04 [0.96-1.14], for non-specific, compared to pancreas specific agents). The prognosis was not dependent on prior acute myocardial infarction or ischemic heart disease (p for interactions >0.3). Conclusions: In current clinical practice, it is unlikely that there are considerable differences in risk of mortality associated with individual sulfonylureas in patients with heart failure.

AB - Aims: The aim was to investigate the outcomes of individual sulfonylureas in patients with heart failure (HF). Methods: All patients hospitalized with HF for the first time in 1997-2006, alive 30 days after discharge, and who received anti-diabetic monotherapy with glimepiride (n= 1097), glibenclamide (glyburide) (n= 1031), glipizide (n= 557), gliclazide (n= 251), or tolbutamide (n= 541) were identified from nationwide registers. Risk of all-cause mortality was assessed by multivariable Cox regression models. Results: Over the median observational time of 744 (Inter Quartile Range 268-1451) days, 2242 patients (64%) died. The analysis demonstrated similar hazard ratio (HR) for mortality for treatment with glimepiride (1.10 [95% confidence interval 0.92-1.33]), glibenclamide (1.12 [0.93-1.34]), glipizide (1.14 [0.93-1.38]), tolbutamide (1.04 [0.85-1.26]), and gliclazide (reference). Grouped according to pancreatic specificity, i.e., with tolbutamide, glipizide, and gliclazide as specific, and glibenclamide, and glimepiride as non-specific agents, no differential prognosis was found between the two groups (HR 1.04 [0.96-1.14], for non-specific, compared to pancreas specific agents). The prognosis was not dependent on prior acute myocardial infarction or ischemic heart disease (p for interactions >0.3). Conclusions: In current clinical practice, it is unlikely that there are considerable differences in risk of mortality associated with individual sulfonylureas in patients with heart failure.

U2 - 10.1016/j.diabres.2011.07.011

DO - 10.1016/j.diabres.2011.07.011

M3 - Journal article

C2 - 21831467

SN - 0168-8227

VL - 94

SP - 119

EP - 125

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

IS - 1

ER -

Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this